CINECA IRIS Institutional Research Information System
IRIS è la soluzione IT che facilita la raccolta e la gestione dei dati relativi alle attività e ai prodotti della ricerca. Fornisce a ricercatori, amministratori e valutatori gli strumenti per monitorare i risultati della ricerca, aumentarne la visibilità e allocare in modo efficace le risorse disponibili.
EnglishThe burden of rare tumors in Europe is still unknown and no generally accepted definition of them exist. The Surveillance of Rare Cancers in Europe project (funded by the European Commission) aimed at providing a definition of "rare cancer", a list of cancers and rare cancer burden indicators, based on population-based cancer registry data, across Europe. An international consensus group agreed that incidence is the most appropriate indicator for measuring rare cancers frequency and set the threshold for rarity at 6/100,000/year. The list of rare cancers was based on the International Classification of Diseases for Oncology (ICD-O 3rd edition) and it was hierarchically structured in 2 layers based on various combinations of ICD-O morphology and topography codes: layer (1) families of tumors (relevant for the health care organisation) and layer (2) tumors clinically meaningful (relevant for clinical decision making and research). The burden indicators were estimated and are provided in this chapter.
Scheda prodotto non validato
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo
| Data di pubblicazione: | 2010 | |
| Titolo: | The burden of rare cancers in Europe. | |
| Autori: | Gatta G;Capocaccia R;Trama A;Martínez-García C;RARECARE Working Group (Hackl M; Zielonk N; Van Eycken E; Henau K; Schrijvers D; Sundseth H; Geissler J; Blaes P; Marreaude S; Audisio R; Znaor A; Mägi M; Hedelin G; Velten M; Launoy G; Guizard AV; Fairvre J; Bouvier AM; Maynadiá M; Manivet I; Mercier M; Buemi A; Tretarre B; Colonna M; Molinié F; Lacour B; Bara S; Schvart C; Ganry O; Grosclaude P; Benhamou E; Grossgoupil M; Coquard IR; Droz JP; Baconnier S; Holleczek B; Wartenberg M; Hehlmann R; Tryggvadottir L; Comber H; Deady S; Bellù F; Ferretti S; Serraino D; Vercelli M; Quaglia A; Vitarelli S; Federico M; Cirilli C; Fusco M; Traina A; Michiara M; Bozzani F; Giacomin A; Tumino R; Cilia S; Spata E; Mangone L; Falcini F; Foca F; Senatore G; Iannelli A; Budroni M; Piffer S; Franchini S; Crocetti E; Caldarella A; La Rosa F; Stracci F; Contiero P; Tagliabue G; Zambon P; Fiore A; Berrino F; Casali PG; Gatta G; Gronchi A; Licitra L; Olmi P; Ruzza M; Sowe S; Trama A; Capocaccia R; De Angelis R; Mallone S; Tavilla A; Dei Tos AP; Fleming J; Brandes AA; England K; Langmark F; Bray F; Rachtan J; Gozdz S; Mezyk R; Zwierko M; Bielska-Lasota M; Slowinski J; Miranda A; Primic-zakelj M; Ondrusova M; Mateos A; Izarzugaza I; Martínez R; Marcos-Gragera R; Sánchez MJ; Navarro C; Chirlaque MD; Ardanaz E; Mareno C; Galceran J; Virizuela-Echaburu JA; Gonzalez-Campora R; Martínez-García C; Melchor JM; Cervantes A; Adolfsson J; Lambe M; Möller TR; Ringborg U; Jundt G; Usel M; Frick H; Ess SM; Bordoni A; Luthi JC; Dehler S; Lutz JM; Visser O; Otter R; Siesling S; van der Zwan JM; Coeberg JW; Sollie A; Schouten H; Greenberg DC; Forman D; Roche M; Verne J; Meechan D; Lawrence G; Coleman MP; Mackay J; Gavin A; Brewster DH; Black RJ; Kunkler I; Steward J; White C) | |
| Rivista: | ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY | |
| Abstract: | The burden of rare tumors in Europe is still unknown and no generally accepted definition of them exist. The Surveillance of Rare Cancers in Europe project (funded by the European Commission) aimed at providing a definition of "rare cancer", a list of cancers and rare cancer burden indicators, based on population-based cancer registry data, across Europe. An international consensus group agreed that incidence is the most appropriate indicator for measuring rare cancers frequency and set the threshold for rarity at 6/100,000/year. The list of rare cancers was based on the International Classification of Diseases for Oncology (ICD-O 3rd edition) and it was hierarchically structured in 2 layers based on various combinations of ICD-O morphology and topography codes: layer (1) families of tumors (relevant for the health care organisation) and layer (2) tumors clinically meaningful (relevant for clinical decision making and research). The burden indicators were estimated and are provided in this chapter. | |
| Handle: | http://hdl.handle.net/11392/2154227 | |
| Appare nelle tipologie: | 03.1 Articolo su rivista |
File in questo prodotto:
http://hdl.handle.net/11392/2154227
Copyright © 2022